Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Machens

Showing results (21-30 of 157) with videos related to

Pageof 16
Sort By:
Annals of Surgical Oncology|October 17, 2009
RET germline mutations in codon 609 and MEN2A phenotype: are they all created equal?Andreas Machens, Henning Dralle
The Journal of Clinical Endocrinology and Metabolism|June 28, 2018
Letter to the Editor: "p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer"Andreas Machens, Henning Dralle
Best Practice & Research. Clinical Endocrinology & Metabolism|December 2, 2008
Surgical approaches in thyroid cancer and lymph-node metastasesHenning Dralle, Andreas Machens
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Bronchoalveolar lavage for diagnosis of miliary lung metastases from papillary thyroid carcinomaAndreas Machens, Henning Dralle
The Journal of Clinical Endocrinology and Metabolism|March 27, 2010
Biomarker-based risk stratification for previously untreated medullary thyroid cancerAndreas Machens, Henning Dralle
European Journal of Endocrinology|May 8, 2010
Decreasing tumor size of thyroid cancer in Germany: institutional experience 1995-2009Andreas Machens, Henning Dralle
European Journal of Endocrinology|March 11, 2024
Accelerated MEN2A in homozygous RET carriers in the context of consanguinityAndreas Machens, Henning Dralle
Endocrine|September 30, 2024
Translating the desmoplastic microenvironment of medullary thyroid cancer into surgical practiceAndreas Machens, Henning Dralle
Surgery|December 7, 2024
Letter to the editor: "Is desmoplastic stromal reaction useful to modulate lymph node dissection in sporadic medullary thyroid carcinoma?"Andreas Machens, Henning Dralle
Current Opinion in Oncology|November 17, 2023
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker resultsAndreas Machens, Henning Dralle
Pageof 16

Showing results (21-30 of 157) with videos related to

Sort By:
Pageof 16
Annals of Surgical Oncology|October 17, 2009
RET germline mutations in codon 609 and MEN2A phenotype: are they all created equal?Andreas Machens, Henning Dralle
The Journal of Clinical Endocrinology and Metabolism|June 28, 2018
Letter to the Editor: "p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer"Andreas Machens, Henning Dralle
Best Practice & Research. Clinical Endocrinology & Metabolism|December 2, 2008
Surgical approaches in thyroid cancer and lymph-node metastasesHenning Dralle, Andreas Machens
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Bronchoalveolar lavage for diagnosis of miliary lung metastases from papillary thyroid carcinomaAndreas Machens, Henning Dralle
The Journal of Clinical Endocrinology and Metabolism|March 27, 2010
Biomarker-based risk stratification for previously untreated medullary thyroid cancerAndreas Machens, Henning Dralle
European Journal of Endocrinology|May 8, 2010
Decreasing tumor size of thyroid cancer in Germany: institutional experience 1995-2009Andreas Machens, Henning Dralle
European Journal of Endocrinology|March 11, 2024
Accelerated MEN2A in homozygous RET carriers in the context of consanguinityAndreas Machens, Henning Dralle
Endocrine|September 30, 2024
Translating the desmoplastic microenvironment of medullary thyroid cancer into surgical practiceAndreas Machens, Henning Dralle
Surgery|December 7, 2024
Letter to the editor: "Is desmoplastic stromal reaction useful to modulate lymph node dissection in sporadic medullary thyroid carcinoma?"Andreas Machens, Henning Dralle
Current Opinion in Oncology|November 17, 2023
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker resultsAndreas Machens, Henning Dralle
Pageof 16